Group 1 - The core point of the news is that Hangzhou Better has become the largest shareholder of Chuangye Huikang after acquiring 96,525,096 shares, representing 6.23% of the total share capital, and obtaining voting rights for a total of 195,780,282 shares, which is 12.64% of the total share capital [1][2] Group 2 - Prior to the equity change, Hangzhou Better did not hold any shares in the company [2] - After the completion of the equity change, Hangzhou Better holds 96,525,096 shares, accounting for 6.23% of the total share capital, and has the right to exercise voting rights for 99,255,186 shares, which is 6.41% of the total share capital [2] - Hangzhou Better plans to recommend four non-independent directors and two independent director candidates to the company following the share transfer [2]

Core Viewpoint - ST Zhongdi (000609) will resume trading on November 18, 2025, after a temporary suspension due to significant stock price fluctuations and investor concerns [2][4]. Group 1: Stock Performance and Trading Suspension - The stock price of ST Zhongdi increased by 153.19% from October 16 to November 12, 2025, leading to a trading suspension starting November 13, 2025, expected to last no more than three trading days [4][5]. - Prior to the suspension, ST Zhongdi's stock had hit the daily limit up for 19 consecutive trading days [5]. Group 2: Company Ownership and Control Changes - Shenzhen Tianwei Investment Partnership acquired 71.1448 million shares of ST Zhongdi for 255 million yuan, resulting in a change of control of the company [8]. - The new controlling shareholders, Men Hongda and Zhang Wei, are both experienced professionals in the semiconductor industry, which may have contributed to the recent surge in stock price [9]. Group 3: Financial Performance and Risks - For the first three quarters of 2025, ST Zhongdi reported revenue of 134.7122 million yuan, a decrease of 52.64% year-on-year, and a total profit of -151.0695 million yuan, down 41.83% year-on-year [10]. - The company’s net profit attributable to shareholders, excluding non-recurring gains and losses, was -132.3492 million yuan, a decline of 34.12% year-on-year [10]. - If the audited financial results for 2025 show negative values for total profit, net profit, or net assets, the company may face delisting risk [10].

Core Points - The company Chuangye Huikang (300451.SZ) has signed a share transfer agreement with Hangzhou Genghao, acquiring 96,525,096 shares, which represents 6.23% of the total share capital [1] - Following the agreement, Hangzhou Genghao will also exercise voting rights for a total of 195,780,282 shares, accounting for 12.64% of the total share capital, making it the largest shareholder of the company [2] Summary by Sections - **Share Transfer Agreement** - On November 12, 2025, Hangzhou Genghao signed a share transfer agreement with Mr. Ge Hang, acquiring 96,525,096 shares [1] - This acquisition gives Hangzhou Genghao a 6.23% stake in the company [1] - **Voting Rights Delegation** - Hangzhou Genghao will exercise voting rights for 99,255,186 shares, which is 6.41% of the total share capital [2] - Additionally, Hangzhou Genghao will also receive voting rights from Jinfu Yuan for 40,000,000 shares, totaling 2.58% of the total share capital [1] - **Change in Control** - After the completion of the agreements, Hangzhou Genghao will become the largest shareholder and plans to propose four non-independent directors and two independent directors to the board [2] - If all proposed directors are elected, Hangzhou Genghao could gain control of the company [2]

Core Viewpoint - The recent announcement by Haocen Medical indicates a change in control, leading to a state of no actual controller, amidst ongoing financial struggles and legal disputes. Group 1: Control Change - Haocen Medical's largest shareholder, Guangzhou Huiyin Rifen Investment Partnership, has undergone a control change, resulting in the company having no actual controller [1][3] - The control change stems from a long-standing cooperation dispute between Huiyin Aofeng and Beijing Shoutuo Ronghui, which was confirmed by a court ruling [2][3] Group 2: Financial Performance - Haocen Medical has reported continuous losses for five consecutive years, with cumulative losses exceeding 700 million yuan from 2020 to 2024 [6] - In the first three quarters of 2025, the company achieved a revenue of 527 million yuan, a year-on-year decrease of 17.0%, with a net profit loss of 26.41 million yuan, a decline of 295.7% [7] Group 3: Business Challenges - The decline in the core dental medical service business is a significant factor in the company's revenue drop, with this segment accounting for 91.98% of total revenue and experiencing a 17.39% year-on-year decrease in the first half of 2025 [8] - Haocen Medical's subsidiary, Delun Medical, has faced a court-ordered freeze on 51% of its shares due to a creditor dispute, which poses risks to the company's operations [9] Group 4: Attempts at Recovery - The company has made unsuccessful attempts to recover financially, including failed auctions of bank shares and attempts to secure loans, which have not alleviated its financial strain [10]

上述协议签署后，杭州更好与葛航形成一致行动人关系。2025年11月14日，杭州更好与锦福源（海 南）私募基金管理合伙企业（有限合伙）（作为锦福源长弓五号私募证券投资基金管理人）（以下简 称"锦福源"）签署了《关于创业慧康科技股份有限公司的表决权委托暨一致行动协议》，约定锦福源将 其持有的公司40,000,000股股份（约占公司总股本的2.58%）对应的全部表决权委托给杭州更好行使。 上述协议签署后，杭州更好与锦福源形成一致行动人关系。上述葛航、锦福源分别将其持有的全部公司 股份对应的表决权委托给杭州更好行使，合称"表决权委托"。 根据上述协议和杭州更好出具的说明，表决权委托完成后，杭州更好将拥有公司12.64%股份对应 的全部表决权，成为公司第一大股东，杭州更好将与公司商议择机启动向特定对象发行事项（"向特定 对象发行股票"）。本次协议转让股份过户后，杭州更好拟向公司提名四名非独立董事、两名独立董事 人选（"董事会改选"）。无论公司是否完成向特定对象发行股票事项，若杭州更好提名的上述董事全部 当选且占公司董事会席位的半数以上，将导致公司控制权变更，杭州更好成为公司的控股股东。为确保 本次权益变动过渡期间公司业 ...

根据上述协议和杭州更好出具的说明，表决权委托完成后，杭州更好将拥有公司12.64%股份对应的全 部表决权，成为公司第一大股东，杭州更好将与公司商议择机启动向特定对象发行事项("向特定对象发 行股票")。本次协议转让股份过户后，杭州更好拟向公司提名四名非独立董事、两名独立董事人选("董 事会改选")。无论公司是否完成向特定对象发行股票事项，若杭州更好提名的上述董事全部当选且占公 司董事会席位的半数以上，将导致公司控制权变更，杭州更好成为公司的控股股东。为确保本次权益变 动过渡期间公司业务经营的连续性及核心管理和技术团队的稳定性，转让方、受让方及公司将就具体实 施方案进行磋商。 2025年11月12日，杭州更好与公司第一大股东、持股5%以上股东葛航签署了《股份转让协议》，约定 葛航将通过协议转让的方式向杭州更好转让公司96,525,096股股份(约占公司总股本的6.23%)，每股转让 价格为人民币5.18元("协议转让")，不低于公司前一交易日(2025年11月7日)股票收盘价的80%；同日， 杭州更好与葛航签署了《关于创业慧康科技股份有限公司的表决权委托暨一致行动协议》，约定葛航将 持有的公司155,780,2 ...

同时，葛航将1.56亿股股份(约占公司总股本的10.06%)的表决权不可撤销地全权委托给杭州更好行使。 11月14日，杭州更好与锦福源(海南)私募基金管理合伙企业签署表决权委托暨一致行动协议，锦福源将 其持有的公司4000万股股份(约占公司总股本的2.58%)对应的全部表决权委托给杭州更好行使。表决权 委托完成后，杭州更好将拥有公司12.64%股份对应的全部表决权，成为公司第一大股东，杭州更好将 与公司商议择机启动向特定对象发行事项。 创业慧康（300451）(300451.SZ)发布公告，2025年11月12日，公司股东葛航与杭州更好智投管理咨询 合伙企业(有限合伙)签署股份转让协议，葛航将通过协议转让方式向杭州更好转让公司9652.51万股股份 (约占公司总股本的6.23%)，每股转让价格为人民币5.18元。 此次协议转让事项尚需提交相关部门审核及办理过户手续。公司筹划控制权变更事项仍在进行中，协议 转让、董事会改选、向特定对象发行股票等事项能否最终实施完成及实施结果尚存在不确定性。公司股 票将于2025年11月17日开市起复牌。 ...

根据上述协议和杭州更好出具的说明，表决权委托完成后，杭州更好将拥有公司12.64%股份对应的全 部表决权，成为公司第一大股东，杭州更好将与公司商议择机启动向特定对象发行事项。本次协议转让 股份过户后，杭州更好拟向公司提名四名非独立董事、两名独立董事人选。无论公司是否完成向特定对 象发行股票事项，若杭州更好提名的上述董事全部当选且占公司董事会席位的半数以上，将导致公司控 制权变更，杭州更好成为公司的控股股东。 创业慧康表示，公司筹划控制权变更事项仍在进行中，协议转让、董事会改选、向特定对象发行股票等 事项能否最终实施完成及实施结果尚存在不确定性。公司将严格按照有关法律法规的规定和要求，根据 后续进展情况认真履行信息披露义务，及时做好信息披露工作。 同时，11月14日，杭州更好与锦福源（海南）私募基金管理合伙企业（有限合伙）（作为锦福源长弓五 号私募证券投资基金管理人）（以下简称"锦福源"）签署了《关于创业慧康科技股份有限公司的表决权 委托暨一致行动协议》，约定锦福源将其持有的公司4000万股股份（约占公司总股本的2.58%）对应的 全部表决权委托给杭州更好行使。上述协议签署后，杭州更好与锦福源形成一致行动人关系 ...

Core Viewpoint - The announcement details the planned transfer of shares and change of control at Honghe Technology Co., Ltd, with a significant stake being acquired by Anhui Ruicheng Hongtu Equity Investment Fund Partnership [1][3][4] Group 1: Share Transfer Agreement - On June 10, 2025, Hefei Ruicheng Private Fund Management Co., Ltd signed a share transfer agreement with the actual controllers and major shareholders of Honghe Technology, involving the acquisition of 59,159,978 shares, representing 25.00% of the total shares [3][4] - Zhang Shujing agreed to waive voting rights for an additional 17,860,872 shares, which is 7.55% of the total shares [3][4] Group 2: Change of Control - Following the completion of the share transfer, Hefei Ruicheng will become the indirect controlling shareholder, and the actual control will shift from Xing Xiuqing and Xing Zheng to no actual controller [4] - The involved parties have issued a commitment letter stating they do not seek control over the listed company [3][4] Group 3: Progress of the Transaction - On October 31, 2025, supplementary agreements were signed to further the share transfer process [5] - As of November 12, 2025, the fund has completed registration with the Asset Management Association of China [6][7]

Core Viewpoint - The company Huayuan Communication (000586.SZ) is planning to issue A-shares to specific investors, which may lead to a change in control of the company [1] Group 1 - The company has announced that its stock will be suspended for trading on November 12 and 13, 2025, due to the ongoing preparations for the issuance of A-shares [1] - During the suspension period, all relevant parties are actively working on this significant matter, and no related transaction agreements have been signed yet [1] - The company anticipates that it will not resume trading on November 14, 2025, and has applied for an extension of the trading suspension, which is expected to last no more than three trading days [1]